TH.TO
Theratechnologies Inc. [TH.TO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
TH.TO Stock Summary
Top 10 Correlated ETFs
TH.TO
Top 10 Correlated Stocks
TH.TO
In the News
TH.TO Financial details
Company Rating
Neutral
Market Cap
52.52M
Income
-29.13M
Revenue
79.73M
Book val./share
-1.72
Cash/share
0.95
Dividend
-
Dividend %
-
Employees
144
Optionable
No
Shortable
Yes
Earnings
26 Feb 2024
P/E
-1.33
Forward P/E
-3.74
PEG
2.84
P/S
0.48
P/B
-0.93
P/C
2.28
P/FCF
-3.81
Quick Ratio
0.33
Current Ratio
0.42
Debt / Equity
-1.4
LT Debt / Equity
-0.02
-
-
EPS (TTM)
-0.32
EPS next Y
-0.58
EPS next Q
-0.12
EPS this Y
47.06%
EPS next Y
78.96%
EPS next 5Y
78.96%
EPS last 5Y
53.02%
Revenue last 5Y
12.67%
Revenue Q/Q
18.84%
EPS Q/Q
-69.2%
-
-
-
-
SMA20
35.8%
SMA50
-21.71%
SMA100
-51.75%
Inst Own
0%
Inst Trans
0%
ROA
-51%
ROE
84%
ROC
0.46%
Gross Margin
74%
Oper. Margin
-24%
Profit Margin
-37%
Payout
-
Shs Outstand
24.2M
Shs Float
14.52M
-
-
-
-
Target Price
-
52W Range
1.22-6.48
52W High
-63.83%
52W Low
+117%
RSI
54.1
Rel Volume
0.25
Avg Volume
84.46K
Volume
21.4K
Perf Week
-3.56%
Perf Month
61.94%
Perf Quarter
-56.94%
Perf Half Y
-57.95%
-
-
-
-
Beta
1.606
-
-
Volatility
0.05%, 0.31%
Prev Close
0.93%
Price
2.17
Change
0.46%
TH.TO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-11-30
| Metric | History | 2018-11-30 | 2019-11-30 | 2020-11-30 | 2021-11-30 | 2022-11-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.58 | 0.82 | 0.86 | 0.76 | 0.84 | |
| Net income per share | -0.06 | -0.23 | -0.29 | -0.34 | -0.5 | |
| Operating cash flow per share | 0 | -0.04 | -0.18 | -0.16 | -0.15 | |
| Free cash flow per share | 0 | -0.09 | -0.18 | -0.16 | -0.16 | |
| Cash per share | 0.64 | 0.53 | 0.27 | 0.44 | 0.35 | |
| Book value per share | 0.46 | 0.32 | 0.04 | 0.19 | -0.24 | |
| Tangible book value per share | 0.26 | -0.19 | -0.37 | -0.07 | -0.39 | |
| Share holders equity per share | 0.46 | 0.32 | 0.04 | 0.19 | -0.24 | |
| Interest debt per share | 0.68 | 0.99 | 0.79 | 0.68 | 0.77 | |
| Market cap | 1.88B | 940.77M | 713.8M | 1.21B | 830.84M | |
| Enterprise value | 1.89B | 962.85M | 756.45M | 1.25B | 873.69M | |
| P/E ratio | -414.34 | -53.8 | -31.49 | -38.26 | -17.59 | |
| Price to sales ratio | 42.55 | 14.88 | 10.81 | 17.38 | 10.38 | |
| POCF ratio | -5.61K | -277.43 | -52.66 | -83.85 | -56.55 | |
| PFCF ratio | -5.02K | -134.15 | -52.54 | -82.89 | -53 | |
| P/B Ratio | 53.53 | 37.88 | 221.4 | 68.35 | -36.81 | |
| PTB ratio | 53.53 | 37.88 | 221.4 | 68.35 | -36.81 | |
| EV to sales | 42.78 | 15.23 | 11.45 | 17.9 | 10.91 | |
| Enterprise value over EBITDA | 1.87K | 24.07K | -82.42 | -76.59 | -32.17 | |
| EV to operating cash flow | -5.64K | -283.94 | -55.81 | -86.36 | -59.47 | |
| EV to free cash flow | -5.05K | -137.3 | -55.68 | -85.38 | -55.73 | |
| Earnings yield | 0 | -0.02 | -0.03 | -0.03 | -0.06 | |
| Free cash flow yield | 0 | -0.01 | -0.02 | -0.01 | -0.02 | |
| Debt to equity | 1.41 | 2.87 | 17.18 | 3.2 | -2.96 | |
| Debt to assets | 0.44 | 0.61 | 0.55 | 0.48 | 0.72 | |
| Net debt to EBITDA | 10.16 | 552 | -4.65 | -2.23 | -1.58 | |
| Current ratio | 2.74 | 2.05 | 1.55 | 2.04 | 0.64 | |
| Interest coverage | -1.38 | -1.49 | -3.35 | -4.46 | -6.14 | |
| Income quality | 0.07 | 0.27 | 0.6 | 0.46 | 0.31 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.13 | 0.13 | 0.19 | 0.21 | 0.22 | |
| Research and developement to revenue | 0.18 | 0.17 | 0.27 | 0.4 | 0.46 | |
| Intangibles to total assets | 0.14 | 0.34 | 0.32 | 0.2 | 0.16 | |
| Capex to operating cash flow | 0.12 | 1.07 | 0 | 0.01 | 0.07 | |
| Capex to revenue | 0 | -0.06 | 0 | 0 | -0.01 | |
| Capex to depreciation | -0.01 | -0.48 | 0 | -0.02 | -0.08 | |
| Stock based compensation to revenue | 0.02 | 0.02 | 0.02 | 0.03 | 0.05 | |
| Graham number | 0.79 | 1.28 | 0.53 | 1.22 | 1.63 | |
| ROIC | -0.03 | -0.11 | -0.29 | -0.33 | -0.87 | |
| Return on tangible assets | -0.05 | -0.22 | -0.33 | -0.33 | -0.6 | |
| Graham Net | -0.18 | -0.44 | -0.7 | -0.42 | -0.67 | |
| Working capital | 46.79M | 39.04M | 22.89M | 46.83M | -40.91M | |
| Tangible asset value | 19.92M | -14.85M | -28.63M | -6.07M | -37.58M | |
| Net current asset value | -2.5M | -16.54M | -32.11M | -9.54M | -42.46M | |
| Invested capital | 1.41 | 2.87 | 17.18 | 3.2 | -2.96 | |
| Average receivables | 9.27M | 10.54M | 11.65M | 12.06M | 11.64M | |
| Average payables | 10.51M | 14.35M | 15.31M | 16.52M | 14.21M | |
| Average inventory | 9.18M | 16.01M | 23.04M | 27.14M | 24.41M | |
| Days sales outstanding | 90.76 | 58.41 | 72.86 | 57.13 | 56.28 | |
| Days payables outstanding | 439.02 | 183.45 | 237.57 | 243.64 | 178.98 | |
| Days of inventory on hand | 312.26 | 292.95 | 341.16 | 457.29 | 273.45 | |
| Receivables turnover | 4.02 | 6.25 | 5.01 | 6.39 | 6.49 | |
| Payables turnover | 0.83 | 1.99 | 1.54 | 1.5 | 2.04 | |
| Inventory turnover | 1.17 | 1.25 | 1.07 | 0.8 | 1.33 | |
| ROE | -0.13 | -0.7 | -7.03 | -1.79 | 2.09 | |
| Capex per share | 0 | -0.05 | 0 | 0 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-08-31 for Q3
| Metric | History | 2022-08-31 | 2022-11-30 | 2023-02-28 | 2023-05-31 | 2023-08-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.22 | 0.23 | 0.21 | 0.18 | 0.86 | |
| Net income per share | -0.08 | -0.08 | -0.11 | -0.1 | -0.03 | |
| Operating cash flow per share | -0.01 | -0.09 | -0.03 | -0.04 | 0.22 | |
| Free cash flow per share | -0.02 | -0.09 | -0.04 | -0.04 | 0.22 | |
| Cash per share | 0.38 | 0.35 | 0.3 | 0.26 | 0.95 | |
| Book value per share | -0.19 | -0.24 | -0.33 | -0.43 | -1.72 | |
| Tangible book value per share | -0.19 | -0.4 | -0.33 | -0.43 | -1.72 | |
| Share holders equity per share | -0.19 | -0.24 | -0.33 | -0.43 | -1.72 | |
| Interest debt per share | 0.71 | 0.72 | 0.71 | 0.71 | 2.52 | |
| Market cap | 842.01M | 829.77M | 367.54M | 345.58M | 22.11M | |
| Enterprise value | 885.03M | 872.63M | 413.5M | 395.3M | 65.38M | |
| P/E ratio | -27.88 | -26.16 | -8.8 | -8.63 | -7.41 | |
| Price to sales ratio | 40.46 | 38.74 | 18.46 | 19.69 | 1.06 | |
| POCF ratio | -704.02 | -100.65 | -110.07 | -97.02 | 4.15 | |
| PFCF ratio | -464.94 | -100.4 | -103.21 | -94.86 | 4.16 | |
| P/B Ratio | -46.62 | -36.76 | -11.37 | -8.32 | -0.53 | |
| PTB ratio | -46.62 | -36.76 | -11.37 | -8.32 | -0.53 | |
| EV to sales | 42.53 | 40.74 | 20.77 | 22.53 | 3.14 | |
| Enterprise value over EBITDA | -192.06 | -189.45 | -97.04 | -58.06 | 60.32 | |
| EV to operating cash flow | -739.99 | -105.85 | -123.84 | -110.98 | 12.27 | |
| EV to free cash flow | -488.7 | -105.58 | -116.12 | -108.51 | 12.3 | |
| Earnings yield | -0.01 | -0.01 | -0.03 | -0.03 | -0.03 | |
| Free cash flow yield | 0 | -0.01 | -0.01 | -0.01 | 0.24 | |
| Debt to equity | -3.68 | -2.96 | -2.04 | -1.61 | -1.4 | |
| Debt to assets | 0.69 | 0.72 | 0.83 | 0.97 | 1.03 | |
| Net debt to EBITDA | -9.34 | -9.3 | -10.79 | -7.3 | 39.92 | |
| Current ratio | 1.05 | 0.64 | 0.84 | 0.72 | 0.42 | |
| Interest coverage | -3.57 | -2.53 | -2.33 | -3.2 | 0.02 | |
| Income quality | 0.16 | 1.04 | 0.32 | 0.36 | -7.14 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.2 | 0.18 | 0.22 | 0.21 | 0.18 | |
| Research and developement to revenue | 0.4 | 0.44 | 0.47 | 0.59 | 0.26 | |
| Intangibles to total assets | 0.13 | 0.16 | 0.18 | 0.2 | 0.23 | |
| Capex to operating cash flow | 0.51 | 0 | 0.07 | 0.02 | 0 | |
| Capex to revenue | -0.03 | 0 | -0.01 | 0 | 0 | |
| Capex to depreciation | -0.72 | -0.02 | -0.24 | -0.09 | -0.02 | |
| Stock based compensation to revenue | 0.04 | 0.04 | 0.03 | 0.04 | 0.02 | |
| Graham number | 0.58 | 0.67 | 0.9 | 1 | 1.09 | |
| ROIC | -0.11 | -0.13 | -0.16 | -0.31 | 0 | |
| Return on tangible assets | -0.09 | -0.1 | -0.16 | -0.18 | -0.02 | |
| Graham Net | -0.6 | -0.67 | -0.69 | -0.72 | -2.7 | |
| Working capital | 3.38M | -40.91M | -12.01M | -20.19M | -57.09M | |
| Tangible asset value | -30.91M | -37.58M | -46.58M | -55.06M | -54.56M | |
| Net current asset value | -36.04M | -42.46M | -50.62M | -59.14M | -57.83M | |
| Invested capital | -3.68 | -2.96 | -2.04 | -1.61 | -1.4 | |
| Average receivables | 12.19M | 11.94M | 11.36M | 11.99M | 11.36M | |
| Average payables | 42.32M | 26.98M | 23.48M | 33.84M | 32.03M | |
| Average inventory | 24.06M | 21.41M | 17.4M | 12.14M | 7.94M | |
| Days sales outstanding | 49.86 | 51.86 | 46.94 | 69.76 | 39.34 | |
| Days payables outstanding | 698.57 | 196.27 | 653.63 | 616.1 | 551.87 | |
| Days of inventory on hand | 393.55 | 299.87 | 289.77 | 167.97 | 121.82 | |
| Receivables turnover | 1.8 | 1.74 | 1.92 | 1.29 | 2.29 | |
| Payables turnover | 0.13 | 0.46 | 0.14 | 0.15 | 0.16 | |
| Inventory turnover | 0.23 | 0.3 | 0.31 | 0.54 | 0.74 | |
| ROE | 0.42 | 0.35 | 0.32 | 0.24 | 0.02 | |
| Capex per share | -0.01 | 0 | 0 | 0 | 0 |
TH.TO Frequently Asked Questions
What is Theratechnologies Inc. stock symbol ?
Theratechnologies Inc. is a CA stock , located in Montreal of Qc and trading under the symbol TH.TO
What is Theratechnologies Inc. stock quote today ?
Theratechnologies Inc. stock price is $2.17 today.
Is Theratechnologies Inc. stock public?
Yes, Theratechnologies Inc. is a publicly traded company.
Company Profile
- Volume Average 84.46K
- Market Capitalization 52.52M
- Employee 144
- CEO Mr. Paul Lévesque
- Headquarters Montreal,QC,CA
- IPO Date 1996-08-06
-
Website
https://www.theratech.com 
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
